Roche ends two Huntington’s disease drug programmes after disappointing results
⏱️ 10 min read | Roche announced it is stopping development of two of its huntingtin-lowering ASO drugs, tominersen and RG6496. This marks a disappointing end to an important chapter in HD clinical research. Read more
Are we finally getting that PET we’ve always wanted?
⏱️8 min read | For the past 20 years, PET tracers have been a game-changer for Alzheimer’s disease, making it possible to see amyloid plaques in the brain without invasive procedures. So what about Huntington’s? Read more
Skyhawk Shares A Closer Look at SKY-0515 Data, Plus A Peek At Expanding US Trial Access
⏱️ 6 min read | New 12-month data from Skyhawk’s SKY-0515 is in and all four measures that make up the cUHDRS are at or above baseline, beating expected natural decline. Plus, a first look at expanding US trial sites. Read more
June 2026: This Month in Huntington’s Disease Research
⏱️ 10 min read | From the clinic, we heard from uniQure about their recent FDA meeting, a stem cell trial dosed its first participant, and Skyhawk shared data on SKY-0515. In the lab, the science of slowing HD at the DNA level keeps building. Read more
Precision Pruning with PROTACs: Selective Targeting of Toxic Huntingtin
⏱️6 min read | PROTACs act like a precision pruning tool, trimming away toxic huntingtin protein while leaving the healthy form intact. In cells and HD mice, this targeted clean-up improved health and slowed disease features. Read more
Your DNA Shouldn’t Cost You Your Insurance: What HD Families Need to Know
⏱️13 min read | Australia just made history by banning life insurers from using genetic testing against you. But for HD families in other countries, the laws meant to protect haven’t kept pace with the science. Let’s break down what you need to know. Read more
EN 
ES 
IT 
DE 
FR